Understand the source comparison
KLOW Tendon Healing Protocol Dosage Timing: Comparison Table
| Peptide | Dosage Range | Administration Frequency | Timing Relative to Injury | Injection Site Proximity | Primary Mechanism | Professional Assessment ||—|—|—|—|—|—|| BPC-157 | 250–500mcg | Once daily | Begin 12–16 hours post-injury | Within 2 inches of inju
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Peptide | Dosage Range | Administration Frequency | Timing Relative to Injury | Injection Site Proximity | Primary Mechanism | Professional Assessment ||—|—|—|—|—|—|| BPC-157 | 250–500mcg | Once daily | Begin 12–16 hours post-injury | Within 2 inches of injury | VEGF receptor upregulation, angiogenesis during inflammatory phase | Essential for vascular foundation. Without it, TB-500 drives migration into under-perfused tissue || TB-500 | 2–5mg | Twice weekly (every 3.5 days) | Begin day 3–5 of protocol | Within 4–6 inches of injury | Actin polymerisation, cell migration during proliferative phase | Drives tissue remodelling but depends on BPC-157 establishing vasculature first || Combined KLOW | BPC-157 daily + TB-500 biweekly | BPC daily, TB every 3.5 days | Staggered: BPC from day 0, TB from day 3 | BPC proximal, TB can be distal | Synergistic: angiogenesis + cellular migration | Timing overlap during days 3–6 produces compounding benefit. Simultaneous start wastes the synergy |
- The table underscores a critical implementation detail: starting both peptides on day 0 is the most common protocol failure. BPC-157 needs 48–72 hours to establish new capillary networks before TB-500 begins driving fibroblast migration. Reversing this sequence or administering simultaneously produces suboptimal collagen deposition.